PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,000 | +63.9% | 5,716 | +128.5% | 0.00% | – |
| Q2 2023 | $36,000 | +176.9% | 2,502 | +32.7% | 0.00% | – |
| Q1 2023 | $13,000 | -71.7% | 1,885 | -54.5% | 0.00% | – |
| Q4 2022 | $46,000 | +1433.3% | 4,139 | +1378.2% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 280 | +115.4% | 0.00% | – |
| Q2 2022 | $1,000 | -94.1% | 130 | -89.5% | 0.00% | – |
| Q1 2022 | $17,000 | -80.5% | 1,244 | -72.0% | 0.00% | – |
| Q4 2021 | $87,000 | +45.0% | 4,447 | +138.1% | 0.00% | – |
| Q3 2021 | $60,000 | +27.7% | 1,868 | +34.7% | 0.00% | – |
| Q2 2021 | $47,000 | +88.0% | 1,387 | +109.5% | 0.00% | – |
| Q1 2021 | $25,000 | – | 662 | +9357.1% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 7 | -65.0% | 0.00% | – |
| Q2 2020 | $1,000 | -92.3% | 20 | -96.1% | 0.00% | – |
| Q1 2020 | $13,000 | -40.9% | 514 | -25.8% | 0.00% | – |
| Q4 2019 | $22,000 | – | 693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |